BACKGROUND: Subclinical rejection and interstitial fibrosis and tubular atrophy (IF/TA) in protocol biopsies are associated with outcome. We study the relationship between histologic lesions in early protocol biopsies and histologic diagnoses in late biopsies for cause. MATERIALS AND METHODS: Renal transplants with a protocol biopsy performed within the first 6 months posttransplant between 1988 and 2006 were reviewed. Biopsies were evaluated according to Banff criteria, and C4d staining was available in biopsies for cause. RESULTS: Of the 517 renal transplants with a protocol biopsy, 109 had a subsequent biopsy for cause which showed the following histological diagnoses: chronic humoral rejection (CHR) (n=44), IF/TA (n=42), recurrence of the primary disease (n=11), de novo glomerulonephritis (n=7), T-cell-mediated rejection (n=4), and polyoma virus nephropathy (n=1). The proportion of retransplants (15.9% vs. 2.3%, P=0.058) and the prevalence of subclinical rejection were higher in patients with CHR than in patients with IF/TA (52.3% vs. 28.6%, P=0.0253). Demographic donor and recipient characteristics and clinical data at the time of protocol biopsy were not different between groups. Logistic regression analysis showed that subclinical rejection (relative risk, 2.52; 95% confidence interval, 1.1-6.3; P=0.047) but not retransplantation (relative risk, 6.7; 95% confidence interval, 0.8-58.8; P=0.085) was associated with CHR. CONCLUSION: Subclinical rejection in early protocol biopsies is associated with late appearance of CHR.
BACKGROUND: Subclinical rejection and interstitial fibrosis and tubular atrophy (IF/TA) in protocol biopsies are associated with outcome. We study the relationship between histologic lesions in early protocol biopsies and histologic diagnoses in late biopsies for cause. MATERIALS AND METHODS: Renal transplants with a protocol biopsy performed within the first 6 months posttransplant between 1988 and 2006 were reviewed. Biopsies were evaluated according to Banff criteria, and C4d staining was available in biopsies for cause. RESULTS: Of the 517 renal transplants with a protocol biopsy, 109 had a subsequent biopsy for cause which showed the following histological diagnoses: chronic humoral rejection (CHR) (n=44), IF/TA (n=42), recurrence of the primary disease (n=11), de novo glomerulonephritis (n=7), T-cell-mediated rejection (n=4), and polyoma virus nephropathy (n=1). The proportion of retransplants (15.9% vs. 2.3%, P=0.058) and the prevalence of subclinical rejection were higher in patients with CHR than in patients with IF/TA (52.3% vs. 28.6%, P=0.0253). Demographic donor and recipient characteristics and clinical data at the time of protocol biopsy were not different between groups. Logistic regression analysis showed that subclinical rejection (relative risk, 2.52; 95% confidence interval, 1.1-6.3; P=0.047) but not retransplantation (relative risk, 6.7; 95% confidence interval, 0.8-58.8; P=0.085) was associated with CHR. CONCLUSION: Subclinical rejection in early protocol biopsies is associated with late appearance of CHR.
Authors: Elena Crespo; Paolo Cravedi; Jaume Martorell; Sergi Luque; Edoardo Melilli; Josep M Cruzado; Marta Jarque; Maria Meneghini; Anna Manonelles; Chiara Donadei; Núria Lloberas; Montse Gomà; Josep M Grinyó; Peter Heeger; Oriol Bestard Journal: Kidney Int Date: 2017-03-06 Impact factor: 10.612
Authors: A I Dipchand; S Webber; K Mason; B Feingold; C Bentlejewski; W T Mahle; R Shaddy; C Canter; E D Blume; J Lamour; W Zuckerman; H Diop; Y Morrison; B Armstrong; D Ikle; J Odim; A Zeevi Journal: Am J Transplant Date: 2018-03-24 Impact factor: 8.086
Authors: S M Kurian; A N Williams; T Gelbart; D Campbell; T S Mondala; S R Head; S Horvath; L Gaber; R Thompson; T Whisenant; W Lin; P Langfelder; E H Robison; R L Schaffer; J S Fisher; J Friedewald; S M Flechner; L K Chan; A C Wiseman; H Shidban; R Mendez; R Heilman; M M Abecassis; C L Marsh; D R Salomon Journal: Am J Transplant Date: 2014-04-11 Impact factor: 8.086
Authors: Joshua Y C Yang; Reuben D Sarwal; Tara K Sigdel; Izabella Damm; Ben Rosenbaum; Juliane M Liberto; Chitranon Chan-On; José M Arreola-Guerra; Josefina Alberu; Flavio Vincenti; Minnie M Sarwal Journal: Sci Transl Med Date: 2020-03-18 Impact factor: 17.956